Skip to main content

Table 3 Reported hypoglycemia in study participants

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Hypoglycemia

LM25  (N = 80)

IGL (N = 82)

Participants with ≥1 episode,

n (%)

Number of episodes per participant year,

mean (SD)

Participants with ≥1 episode,

n (%)

Number of episodes per participant year,

mean (SD)

Overall (≤70 mg/dL)

57 (71.3)

18.9 (27.3)

56 (68.3)

21.6 (31.1)

Documented symptomatic (≤70 mg/dL)

45 (56.3)

9.6 (15.5)

40 (48.8)

11.0 (19.4)

Asymptomatic (≤70 mg/dL)

36 (45.0)

8.5 (17.9)

43 (52.4)

10.2 (20.9)

Nocturnal

24 (30.0)

2.4 (5.8)

22 (26.8)

2.8 (6.5)

Severe

1 (1.3)

0.1 (0.7)

0 (0)

0 (0)

  1. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SD standard deviation